Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EA05
|
| gptkbp:brand |
gptkb:Inrebic
|
| gptkbp:CASNumber |
gptkb:936091-26-8
|
| gptkbp:contraindication |
gptkb:Wernicke's_encephalopathy
|
| gptkbp:developer |
gptkb:Impact_Biomedicines
gptkb:Sanofi gptkb:Celgene |
| gptkbp:hasMolecularFormula |
gptkb:C27H36N6O3S
|
| https://www.w3.org/2000/01/rdf-schema#label |
fedratinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
JAK2 inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
gptkb:encephalopathy nausea vomiting diarrhea thrombocytopenia |
| gptkbp:target |
gptkb:JAK2
gptkb:FLT3 gptkb:RET BRK |
| gptkbp:usedFor |
gptkb:secondary_myelofibrosis
gptkb:myelofibrosis primary myelofibrosis |
| gptkbp:bfsParent |
gptkb:JAK2_mutation
gptkb:myelofibrosis |
| gptkbp:bfsLayer |
6
|